Cell type-dependent biomarker expression in adenoid cystic carcinoma

Cancer

Volumn 116, Issue 24, 2010, Pages 5749-5756

  Bell, Diana ^a   Roberts, Dianna ^a   Kies, Merrill ^a   Rao, Pulivarthi ^b   Weber, Randal S ^a   El Naggar, Adel K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

adenoid cystic carcinoma; c Kit; cellular localization; epidermal growth factor receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MYOEPITHELIUM CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVARY GLAND; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOID CYSTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650086716     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25541     Document Type: Article

References (37)

1. Fordice J, Kershaw C, El-Naggar A, Goepfert H., Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999; 125: 149-152.
2. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001; 96: 149-158.
3. Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE., Adenoid cystic carcinoma of the head and neck-20 years' experience. Int J Oral Maxillofac Surg. 2004; 33: 25-31.
4. Barsky SH, Karlin NJ., Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. J Mammary Gland Biol Neoplasia. 2005; 10: 249-260.
5. Bissell MJ, Kenny PA, Radisky DC., Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005; 70: 343-356.
6. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008; 13: 394-406.
7. Miller FR., Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000; 5: 379-391.
8. Edwards PC, Bhuiya T, Kelsch RD., C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95: 586-593.
9. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr., KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999; 12: 956-960.
10. Mino M, Pilch BZ, Faquin WC., Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol. 2003; 16: 1224-1231.
11. Guerriere-Kovach PM, Hunt EL, Patterson JW, Glembocki DJ, English JC 3rd, Wick MR,. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol. 2004; 122: 70-77.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580. (Pubitemid 28067289)
13. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol. 1995; 177: 253-258.
14. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol. 2004; 164: 305-313.
15. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M., CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11: 728-734.
16. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004; 22: 4514-4522.
17. Heinrich MC, Blanke CD, Druker BJ, Corless CL., Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002; 20: 1692-1703.
18. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
19. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134.
20. Rao PH, Roberts D, Zhao YJ, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res. 2008; 14: 5181-5187.
21. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21: 2237-2246.
22. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 2149-2158.
23. Perez-Soler R., Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer. 2004; 6 (suppl 1): S20-S23.
24. Arteaga CL,. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002; 7 (4 suppl): 31-39.
25. Ciardiello F, Tortora G,. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7: 2958-2970.
26. Jeng YM, Lin CY, Hsu HC,. Expression of the c-Kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000; 154: 107-111.
27. Salomon DS, Brandt R, Ciardiello F, Normanno N., Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183-232.
28. Pan CC, Chen PC, Chiang H., KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004; 202: 375-381.
29. Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003; 91: 9-14.
30. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O., Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology. 2008; 53: 567-577.
31. Sorensen KB, Godballe C, de Stricker K, Krogdahl A., Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med. 2006; 35: 286-291.
32. Vered M, Braunstein E, Buchner A., Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 2002; 24: 632-636.
33. Macarenco RS, Uphoff TS, Gilmer HF, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol. 2008; 21: 1168-1175.
34. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A., Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of 2 successfully treated cases. Head Neck. 2004; 26: 829-831.
35. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-Kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005; 23: 585-590.
36. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T., [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie. 2002; 81: 98-105.
37. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21: 3798-3807.